Related Experiment Video

Updated: Jul 17, 2026

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity

Ingrid G M Kolfschoten1, Bart van Leeuwen, Katrien Berns

  • 1Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Cell
|June 18, 2005
PubMed

Insights

PITX1 acts as a tumor suppressor by inhibiting the RAS pathway. Low PITX1 expression correlates with cancer, and restoring it reduces tumor growth, revealing a new mechanism in cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Activating RAS mutations drive tumorigenesis, but many cancers have wild-type RAS, suggesting alternative activation mechanisms.
  • Identifying novel tumor suppressor genes is crucial for understanding cancer development and finding new therapeutic targets.

Purpose of the Study:

  • To identify novel tumor suppressor genes involved in cancer development.
  • To investigate the role of PITX1 in RAS pathway regulation and tumorigenesis.

Main Methods:

  • Screened an RNA-interference library for genes whose knockdown transforms human primary cells without oncogenic RAS.
  • Assessed PITX1 expression in human tumors and cancer cell lines.
  • Restored PITX1 expression in colon cancer cells and evaluated its effect on tumorigenicity.
  • Identified RASAL1 as a transcriptional target of PITX1.

Main Results:

  • Identified PITX1 as a novel tumor suppressor gene.
  • Knockdown of PITX1 activates the RAS pathway and promotes tumorigenicity.
  • Low PITX1 expression was observed in prostate, bladder tumors, and wild-type RAS colon cancer cell lines.
  • Restoration of PITX1 inhibited tumorigenicity in a wild-type RAS-dependent manner.
  • PITX1 downregulates the RAS pathway via transcriptional regulation of RASAL1.

Conclusions:

  • PITX1 functions as a tumor suppressor by downregulating the RAS pathway through RASAL1.
  • Dysregulation of the PITX1-RASAL1 axis may contribute to tumorigenesis in cancers with wild-type RAS.

More Related Videos

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...